Risankizumab for The Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from The Czech Republic
mediaposted on 2021-05-28, 14:42 authored by Adis journals on behalf of:, Spyridon Gkalpakiotis, Petra Cetkovska, Petr Arenberger, Tomas Dolezal, Monika Arenbergerova, Barbora Velackova, Jorga Fialova, Martina Kojanova, and the BIOREP study group
Article full text
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.